(NASDAQ: IDYA) Ideaya Biosciences's forecast annual revenue growth rate of -0.17% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.53%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.5%.
Ideaya Biosciences's revenue in 2026 is $218,710,000.On average, 21 Wall Street analysts forecast IDYA's revenue for 2026 to be $3,499,915,860, with the lowest IDYA revenue forecast at $0, and the highest IDYA revenue forecast at $8,667,683,535. On average, 18 Wall Street analysts forecast IDYA's revenue for 2027 to be $10,955,678,009, with the lowest IDYA revenue forecast at $3,958,656,337, and the highest IDYA revenue forecast at $19,496,470,275.
In 2028, IDYA is forecast to generate $19,283,082,189 in revenue, with the lowest revenue forecast at $9,036,063,378 and the highest revenue forecast at $38,890,198,137.